Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), has appointed Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The appointment follows the company's previously announced decision to combine the COO roles for Drug Substances and Drug Products into a single position, aligning with its strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
With his strong track record in integrated operations, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. The company, which operates 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China, reported sales of CHF 1,327.8 million in 2025 and employs over 3,800 people.
"I am very pleased to welcome Eduardo to Siegfried," said Marcel Imwinkelried, Chief Executive Officer of Siegfried. "He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He brings extensive international leadership experience, having lived and worked across Europe and Latin America.
The appointment is significant for Siegfried's customers and the broader pharmaceutical industry as it underscores the company's commitment to streamlining operations and providing seamless services from drug substances to drug products. For more information about Siegfried's integrated solutions, visit www.siegfried.ch.
This change in Siegfried's management team reflects the company's strategic focus on operational excellence and its ability to adapt to the evolving needs of pharmaceutical clients seeking reliable, end-to-end CDMO partnerships. The original announcement is available on www.newmediawire.com.
